clinical trial · NCT06930625
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
Debiopharm International SA·phase3·recruiting·n = 119
AcromegalyDebio 4126Placebo
brief summary
The primary purpose of this study is to assess the effect of Debio 4126 in the maintenance of the levels of insulin-like growth factor 1 (IGF-1) ≤1x upper limit of normal (ULN) in the double-blind period (Period 1) in comparison to placebo at week 36.
started
Nov 26, 2025
primary completion
Jun 1, 2028
completion
Mar 1, 2029
last updated
Mar 30, 2026
official title
A Phase 3 Randomized 3-arm Trial (Double-blind Debio 4126, Placebo Control, and Open-label Debio 4126), to Assess the Efficacy and Safety of Debio 4126, a 12-week Octreotide Formulation, in Patients With Acromegaly Previously Treated With Somatostatin Analogs
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol